portal for all clinical trial submissions and public disclosures. However, the EU Clinical Trials Register remains active for legacy trials approved under the Directive until the transition deadline of January 30, 2025.

Core Clinical Trial Insights on Transparency

1. Transparency Objectives

The key goals of the EU trial registries are:

• Promoting public trust by publishing trial details
• Preventing selective reporting of results
• Supporting evidence-based healthcare decisions
• Enabling patient participation by listing active recruitment trials

2. What Information Is Made Public?

In the EU CTR and CTIS, the following data are typically disclosed:

• Trial identification details (sponsor, protocol number, title)
• Study design and objectives
• Participating Member States and sites
• Recruitment status
• Summary of results
• Layperson summary (required under CTR 536/2014)

Sensitive or proprietary information may be redacted, but sponsors must justify redactions according to EMA’s confidentiality policies.

3. Results Reporting Timelines

Under EU CTR (Directive):

• Results must be posted within 12 months of trial completion.
• For pediatric trials, results must be posted within 6 months.

Under CTR 536/2014 (Regulation):

• Lay summaries must be submitted within 12 months (6 months for pediatric).
• Technical results summaries are also required for public access.

4. Enforcement and Compliance

EMA and Member States monitor compliance with transparency obligations. Sponsors failing to post results within required timelines may face:

• Regulatory queries or rejection of future submissions
• Public identification of non-compliance in CTIS
• Loss of credibility with regulators, investigators, and patients

5. Transparency in Multi-Country Trials

For multi-country EU trials, transparency obligations apply across all participating Member States. Results are harmonized and published centrally in CTIS, eliminating the duplication that existed under the Directive-era system.

Best Practices for Sponsors

• Prepare both technical and lay summaries in parallel with clinical study reports.
• Develop internal SOPs for timely results disclosure.
• Ensure translations of lay summaries meet Member State language requirements.
• Train staff and CROs on CTIS publication processes.
• Maintain redaction strategies in line with EMA guidance on commercial confidentiality.

Scientific and Regulatory Evidence

• Directive 2001/20/EC – Clinical Trials Directive (superseded)
• Regulation (EU) 536/2014 – Clinical Trial Regulation
• EMA Transparency Policy and CTIS guidance documents
• European Commission Q&A on Clinical Trial Regulation
• ICH E3 – Clinical Study Report Structure

Special Considerations

Transparency is especially critical in:

• Pediatric trials, where early disclosure informs treatment guidelines.
• Rare disease trials, where data sharing accelerates research progress.
• COVID-19 vaccine trials, which highlighted the importance of timely public access to trial data.

Data protection under GDPR must also be balanced with transparency, ensuring no identifiable patient information is disclosed in the public domain.

When Sponsors Should Engage Regulators

• When drafting lay summaries to ensure patient-friendly clarity
• If confidentiality claims need validation
• During trial closure to confirm submission obligations
• When planning data sharing beyond CTIS/EU CTR requirements
• If results cannot be posted within regulatory deadlines

FAQs

1. Is EU CTR the same as CTIS?

No. EU CTR refers to the older registry linked to EudraCT under the Directive. CTIS is the new system under CTR 536/2014.

2. Are results of all trials made public?

Yes, unless justified exceptions apply (e.g., confidentiality, national security). Lay summaries are mandatory under CTR 536/2014.

3. What is the deadline for publishing trial results?

12 months for adult trials and 6 months for pediatric trials after completion, unless deferred with approval.

4. Can sponsors redact commercially sensitive information?

Yes, but redactions must follow EMA guidance and be justified scientifically or commercially.

5. How do patients use the EU Clinical Trials Register?

Patients can search ongoing and completed trials, learn about participation opportunities, and review trial outcomes in lay-friendly language.

6. Will EU CTR be retired?

Yes. It will remain accessible until 2025 for Directive-era trials, after which CTIS will fully replace it as the EU’s official registry.

Conclusion

The EU Clinical Trials Register, and now CTIS under CTR 536/2014, serve as key instruments of transparency in European research. They ensure that trial information and results are made accessible to the public, strengthen trust in regulatory oversight, and prevent selective reporting. For sponsors, proactive compliance with disclosure obligations is not just a legal duty but also a commitment to ethical and responsible research.